Regeneron Pharmaceuticals (REGN) FCF Margin (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly FCF Margin of 13.35% for Q2 2026, down 1183.0% year-over-year from 1.23% in Q2 2025, and down 43.26% quarter-over-quarter from 23.53% in Q1 2026.
Regeneron Pharmaceuticals (REGN) FCF Margin (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 13.35% for Q2 2026.
- In Q2 2026, FCF Margin fell 1183.0% year-over-year to 13.35%; the TTM figure through Jun 2026 stood at 28.84% (down 138.0% YoY), while the FY2025 annual figure was 33.47%, up 341.0% from the prior year.
- FCF Margin for Q2 2026 stood at 13.35%, down from 23.53% in the prior quarter.
- The five-year high for FCF Margin was 3919.8% in Q1 2022, with the low at 9.48% in Q2 2024.
- The 5-year median for FCF Margin is 26.06% (2025), against an average of 329.32%.
- The sharpest annual moves came in 2022 and 2023: FCF Margin jumped 389632 bps in 2022, then tumbled 388219 bps in 2023.
- Regeneron Pharmaceuticals' FCF Margin stood at 1567.7% in 2022, then plunged by 98 bps to 24.41% in 2023, then jumped by 80 bps to 44.01% in 2024, then retreated by 4 bps to 42.26% in 2025, then tumbled by 68 bps to 13.35% in 2026.
- Business Quant data shows REGN's FCF Margin at 13.35% in Q2 2026, 23.53% in Q1 2026, and 42.26% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -18,629.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.35% |
| Mar 31, 2026 | 23.53% |
| Dec 31, 2025 | 23.74% |
| Sep 30, 2025 | 30.57% |
| Jun 30, 2025 | 32.51% |
| Mar 31, 2025 | 26.94% |
| Dec 31, 2024 | 28.06% |
| Sep 30, 2024 | 23.83% |
| Jun 30, 2024 | 9.48% |
| Mar 31, 2024 | 43.83% |
| Dec 31, 2023 | 24.41% |
| Sep 30, 2023 | 21.49% |
| Jun 30, 2023 | 35.63% |
| Mar 31, 2023 | 37.61% |
| Dec 31, 2022 | 1,567.70% |
| Sep 30, 2022 | 16.57% |
| Jun 30, 2022 | 14.38% |
| Mar 31, 2022 | 3,919.80% |
| Dec 31, 2021 | 44.78% |
| Sep 30, 2021 | 95.01% |